Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLUG-IN: Enfortumab vedotin plus pembrolizumab in previously treated advanced melanoma
2024-514163-26-00Phase 2Authorised
- Sponsor
- Gem
- Start
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and pembrolizumab in melanoma, sponsored by Gem. Primary endpoint: Objective Response Rate (ORR). Planned start Mar 2025; status: authorised.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-514163-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514163-26-00.